read?file=nice+guidelines+neuroendocrine+tumours << (Read Online)

Neuroendocrine tumours (metastatic, unresectable, progressive) - 177 Lu-dotatate [ID1224]
Neuroendocrine tumours constitute a heterogeneous group of rare tumours. Neuroendocrine tumours can be broadly subdivided into those with and those . neuroendocrine tumours' Proposed NICE technology appraisal. ID 857 Publication date to be confirmed. Related Guidelines: 'Diagnosis and management of
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857] that they are not able to provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal with immediate effect. Timeline. Key events during the development of the guidance:
28 Jun 2017 Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858] Key events during the development of the guidance: NICE cannot release any recommendations on 177Lu-dotatate until it has a positive opinion from the European Medicines Agency's Committee for
Results 1 - 10 of 537 Source: British Society of Gastroenterology - BSG - 03 November 2011 - Publisher: British Society of Gastroenterology. These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with
Results 1 - 50 of 537 Evidence-based information on neuroendocrine tumours from hundreds of trustworthy sources for health and social care. Make better, quicker, evidence based decisions. Evidence search provides access to selected and authoritative evidence in health, social care and public health.
16 Aug 2016 NICE update. UKINETS and the NET Patient Foundation have been involved as stakeholders and are providing input into the following reviews being undertaken by NICE: Multiple Technology Appraisal (MTA) | Neuroendocrine tumours (metastatic, unresectable) – everolimus, lanreotide, lutetium-177 and
Home · NICE Guidance · In development. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]. In development [GID-TA10024] Expected publication date: 28 June 2017. Project information · Project documents. Documents. A list of downloadable documents created during
The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using Lu-177 dotatate for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease in the NHS in England. The appraisal committee has considered the evidence
28 Jun 2017 Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults. The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health

Annons

The photo has no tags

March 2018